Trends in Schizophrenia Diagnosis and Treatment

  • Wolfgang GaebelEmail author
  • Mathias Riesbeck
  • Veronica W. Larach
  • Peter Falkai
  • Jürgen Zielasek


This review provides an overview of the concepts, methods and current status of the classification and diagnosis of schizophrenia and of the guidelines in schizophrenia treatment since the respective previous issue of Advances in Psychiatry had been published in 2009. While research evidence has greatly advanced the understanding of the aetiopathogenesis of schizophrenia, the diagnostic criteria of schizophrenia remain clinical ones. Classification criteria have been revised for the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) of the American Psychiatric Association. These and the revision of the classification of schizophrenia in the upcoming 11th version of the International Classification of Diseases issued by the World Health Organization (ICD-11) will be reviewed. Furthermore, a substantial number of studies have advanced schizophrenia treatment in pharmacotherapy and psychosocial therapies, and this increasing evidence makes it ever more important to establish clear guidelines to assure the transfer of evidence-based diagnostic and therapeutic procedures into clinical practice.


Schizophrenia Diagnosis Classification ICD-11 Treatment Pharmacotherapy Psychotherapy 


Conflicts of Interest Statement

The authors declare that they have no conflicts of interest regarding the contents of this review.


  1. 1.
    Gaebel W, Riesbeck M, Wobrock T. Schizophrenia guidelines across the world: a selective review and comparison. Int Rev Psychiatry. 2011a;23:379–87.CrossRefPubMedGoogle Scholar
  2. 2.
    Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511(7510):421–7.CrossRefGoogle Scholar
  3. 3.
    Hauberg ME, Roussos P, Grove J, Børglum AD, Mattheisen M, Schizophrenia Working Group of the Psychiatric Genomics Consortium. Analyzing the role of MicroRNAs in schizophrenia in the context of common genetic risk variants. JAMA Psychiat. 2016;73(4):369–77.CrossRefGoogle Scholar
  4. 4.
    Schwarz E, Izmailov R, Liò P, Meyer-Lindenberg A. Protein interaction networks link schizophrenia risk loci to synaptic function. Schizophr Bull. 2016;42(6):1334–42.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Liu M, Malone SM, Vaidyanathan U, Keller MC, Abecasis G, McGue M, Iacono WG, Vrieze SI. Psychophysiological endophenotypes to characterize mechanisms of known schizophrenia genetic loci. Psychol Med. 2016;20:1–10.Google Scholar
  6. 6.
    Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, Smieskova R, Studerus E, Kambeitz-Ilankovic L, von Saldern S, Cabral C, Reiser M, Falkai P, Borgwardt S. Detecting the psychosis prodrome across high-risk populations using neuroanatomical biomarkers. Schizophr Bull. 2015;41(2):471–82.CrossRefPubMedGoogle Scholar
  7. 7.
    Zarogianni E, Storkey AJ, Johnstone EC, Owens DG, Lawrie SM. Improved individualized prediction of schizophrenia in subjects at familial high risk, based on neuroanatomical data, schizotypal and neurocognitive features. Schizophr Res. 2017;181:6–12. Scholar
  8. 8.
    Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli JS, Ehrenreich H, Fischer A, Fonteh A, Gattaz WF, Gawlik M, Gerlach M, Grünblatt E, Halene T, Hasan A, Hashimoto K, Kim YK, Kirchner SK, Kornhuber J, Kraus TF, Malchow B, Nascimento JM, Rossner M, Schwarz M, Steiner J, Talib L, Thibaut F, Riederer P, Falkai P, Members of the WFSBP Task Force on Biological Markers. Consensus paper of the WFSBP Task Force on Biological Markers: criteria for biomarkers and endophenotypes of schizophrenia, part III: molecular mechanisms. World J Biol Psychiatry. 2017;18:330–56.CrossRefPubMedGoogle Scholar
  9. 9.
    Schmidt A, Cappucciati M, Radua J, Rutigliano G, Rocchetti M, Dell'Osso L, Politi P, Borgwardt S, Reilly T, Valmaggia L, McGuire P, Fusar-Poli P. Improving prognostic accuracy in subjects at clinical high risk for psychosis: systematic review of predictive models and meta-analytical sequential testing simulation. Schizophr Bull. 2017;43:375–88.PubMedGoogle Scholar
  10. 10.
    Crossley NA, Mechelli A, Ginestet C, Rubinov M, Bullmore ET, McGuire P. Altered hub functioning and compensatory activations in the connectome: a meta-analysis of functional neuroimaging studies in schizophrenia. Schizophr Bull. 2016;42(2):434–42.CrossRefPubMedGoogle Scholar
  11. 11.
    Friston K, Brown HR, Siemerkus J, Stephan KE. The dysconnection hypothesis (2016). Schizophr Res. 2016;176(2–3):83–94.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Klauser P, Baker ST, Cropley VL, Bousman C, Fornito A, Cocchi L, Fullerton JM, Rasser P, Schall U, Henskens F, Michie PT, Loughland C, Catts SV, Mowry B, Weickert TW, Shannon Weickert C, Carr V, Lenroot R, Pantelis C, Zalesky A. White matter disruptions in schizophrenia are spatially widespread and topologically converge on brain network hubs. Schizophr Bull. 2017;43:425–35.PubMedGoogle Scholar
  13. 13.
    Braun U, Schäfer A, Bassett DS, Rausch F, Schweiger JI, Bilek E, Erk S, Romanczuk-Seiferth N, Grimm O, Geiger LS, Haddad L, Otto K, Mohnke S, Heinz A, Zink M, Walter H, Schwarz E, Meyer-Lindenberg A, Tost H. Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function. Proc Natl Acad Sci U S A. 2016;113(44):12568–73.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Cetin MS, Houck JM, Rashid B, Agacoglu O, Stephen JM, Sui J, Canive J, Mayer A, Aine C, Bustillo JR, Calhoun VD. Multimodal classification of schizophrenia patients with MEG and fMRI data using static and dynamic connectivity measures. Front Neurosci. 2016;10:466.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bost C, Pascual O, Honnorat J. Autoimmune encephalitis in psychiatric institutions: current perspectives. Neuropsychiatr Dis Treat. 2016;12:2775–87.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Smyth AM, Lawrie S. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013;11(3):107–17.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Watkins CC, Andrews SR. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res. 2016;176(1):14–22.CrossRefPubMedGoogle Scholar
  18. 18.
    Pollak TA, McCormack R, Peakman M, Nicholson TR, David AS. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis. Psychol Med. 2014;44(12):2475–87.CrossRefPubMedGoogle Scholar
  19. 19.
    Réus GZ, Fries GR, Stertz L, Badawy M, Passos IC, Barichello T, Kapczinski F, Quevedo J. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015;300:141–54.CrossRefGoogle Scholar
  20. 20.
    Volk DW. Role of microglia disturbances and immune-related marker abnormalities in cortical circuitry dysfunction in schizophrenia. Neurobiol Dis. 2016;99:58–65.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Howes OD, McCutcheon R, Owen MJ, Murray RM. The role of genes, stress, and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9–20.CrossRefPubMedGoogle Scholar
  22. 22.
    Zorn JV, Schür RR, Boks MP, Kahn RS, Joëls M, Vinkers CH. Cortisol stress reactivity across psychiatric disorders: a systematic review and meta-analysis. Psychoneuroendocrinology. 2016;77:25–36.CrossRefPubMedGoogle Scholar
  23. 23.
    Haddad L, Schäfer A, Streit F, Lederbogen F, Grimm O, Wüst S, Deuschle M, Kirsch P, Tost H, Meyer-Lindenberg A. Brain structure correlates of urban upbringing, an environmental risk factor for schizophrenia. Schizophr Bull. 2015;41(1):115–22.CrossRefPubMedGoogle Scholar
  24. 24.
    Lederbogen F, Kirsch P, Haddad L, Streit F, Tost H, Schuch P, Wüst S, Pruessner JC, Rietschel M, Deuschle M, Meyer-Lindenberg A. City living and urban upbringing affect neural social stress processing in humans. Nature. 2011;474(7352):498–501.CrossRefPubMedGoogle Scholar
  25. 25.
    Cancel A, Comte M, Truillet R, Boukezzi S, Rousseau PF, Zendjidjian XY, Sage T, Lazerges PE, Guedj E, Khalfa S, Azorin JM, Blin O, Fakra E. Childhood neglect predicts disorganization in schizophrenia through grey matter decrease in dorsolateral prefrontal cortex. Acta Psychiatr Scand. 2015;132(4):244–56.CrossRefPubMedGoogle Scholar
  26. 26.
    Teicher MH, Samson JA, Anderson CM, Ohashi K. The effects of childhood maltreatment on brain structure, function and connectivity. Nat Rev Neurosci. 2016;17(10):652–66.CrossRefPubMedGoogle Scholar
  27. 27.
    O’Hare T, Shen C, Sherrer M. Differences in trauma and posttraumatic stress symptoms in clients with schizophrenia spectrum and major mood disorders. Psychiatry Res. 2013;205(1–2):85–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Ceaser AE, Barch DM. Striatal activity is associated with deficits of cognitive control and aberrant salience for patients with schizophrenia. Front Hum Neurosci. 2016;9:687. Scholar
  29. 29.
    Wang X, Zhang W, Sun Y, Hu M, Chen A. Aberrant intra-salience network dynamic functional connectivity impairs large-scale network interactions in schizophrenia. Neuropsychologia. 2016;93(Pt A):262–70.CrossRefPubMedGoogle Scholar
  30. 30.
    Dudley R, Taylor P, Wickham S, Hutton P. Psychosis, delusions and the “jumping to conclusions” reasoning bias: a systematic review and meta-analysis. Schizophr Bull. 2016;42(3):652–65.CrossRefPubMedGoogle Scholar
  31. 31.
    McLean BF, Mattiske JK, Balzan RP. Association of the jumping to conclusions and evidence integration biases with delusions in psychosis: a detailed meta-analysis. Schizophr Bull. 2017;43:344–54.PubMedGoogle Scholar
  32. 32.
    Van Os J, Reininghaus U, Meyer-Lindenberg A. The search for environmental mechanisms underlying the expression of psychosis: introduction. Schizophr Bull. 2016.
  33. 33.
    Mizrahi R. Social Stress and Psychosis Risk: Common Neurochemical Substrates? Neuropsychopharmacology 2015;41(3):666–74.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Debost JP, Larsen JT, Munk-Olsen T, Mortensen PB, Meyer U, Petersen L. Joint effects of exposure to prenatal infection and peripubertal psychological trauma in schizophrenia. Schizophr Bull. 2017;43:171–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Attademo L, Bernardini F, Garinella R, Compton MT. Environmental pollution and risk of psychotic disorders: A review of the science to date. Schizophr Res. 2017;181:55–9. Scholar
  36. 36.
    Anders S, Kinney DK. Abnormal immune system development and function in schizophrenia helps reconcile diverse findings and suggests new treatment and prevention strategies. Brain Res. 2015;1617:93–112.CrossRefPubMedGoogle Scholar
  37. 37.
    Gaebel W, Zielasek J. Focus on psychosis. Dialogues Clin Neurosci. 2015a;17(1):9–18.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Gaebel W, Zielasek J. Schizophrenia in 2020: trends in diagnosis and therapy. Psychiatry Clin Neurosci. 2015b;69:661–73.CrossRefPubMedGoogle Scholar
  39. 39.
    Waters F, Fernyhough C. Hallucinations: a systematic review of points of similarity and difference across diagnostic classes. Schizophr Bull. 2017;43(1):32–43.CrossRefPubMedGoogle Scholar
  40. 40.
    Kendler KS. The clinical features of paranoia in the 20th century and their representation in diagnostic criteria from DSM-III through DSM-5. Schizophr Bull. 2017;43:332–43. Scholar
  41. 41.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-5. 5th ed. Washington and London: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  42. 42.
    Tandon R, Gaebel W, Barch DM, Bustillo J, Gur RE, Heckers S, Malaspina D, Owen MJ, Schultz S, Tsuang M, Van Os J, Carpenter W. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3–10.CrossRefPubMedGoogle Scholar
  43. 43.
    World Health Organization. The ICD-10 classification of mental and behavioural disorders. Clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation; 1992.Google Scholar
  44. 44.
    International Advisory Group for the Revision of ICD-10 Mental and Behavioural Disorders. A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders. World Psychiatry. 2011;10:86–92.CrossRefPubMedCentralGoogle Scholar
  45. 45.
    Reed GM, Rebello TJ, Pike KM, Medina-Mora ME, Gureje O, Zhao M, et al. WHO’s global clinical practice network for mental health. Lancet Psychiatry. 2015;2:379–80.CrossRefPubMedGoogle Scholar
  46. 46.
    Keeley JW, Reed GM, Roberts MC, Evans SC, Medina-Mora ME, Robles R, et al. Developing a science of clinical utility in diagnostic classification systems field study strategies for ICD-11 mental and behavioral disorders. Am Psychol. 2016;71:3–16.CrossRefPubMedGoogle Scholar
  47. 47.
    Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187:248–55.CrossRefPubMedGoogle Scholar
  48. 48.
    Gaebel W, Zielasek J, Reed GM. Mental and Behavioural disorders in the ICD-11: concepts, methodologies, and current status. Psychiatr Pol. 2017;51:169–95.CrossRefPubMedGoogle Scholar
  49. 49.
    Gaebel W, Zielasek J, Cleveland HR. Classifying psychosis—challenges and opportunities. Int Rev Psychiatry. 2012;24:538–48.CrossRefPubMedGoogle Scholar
  50. 50.
    Gaebel W, Zielasek J, Cleveland HR. Psychotic disorders in ICD-11. Asian J Psychiatr. 2013;6:263–5.CrossRefPubMedGoogle Scholar
  51. 51.
    National Institute for Health and Clinical Excellence (NICE) (2009). Schizophrenia. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update).
  52. 52.
    National Institute for Health and Care Excellence (NICE) (2014). Psychosis and schizophrenia in adults: treatment and management. NICE Clinical Guideline 178.
  53. 53.
    Gaebel W, Riesbeck M. Evidence-based treatment guidelines for the early illness phase in schizophrenia. Early Interv Psychiatry. 2008;2:303–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Melle I, Opjordsmoen S, Simonsen E, Vaglum P. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand. 2001;103:323–34.CrossRefPubMedGoogle Scholar
  55. 55.
    Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Valmaggia L, Barale F, Caverzasi E, McGuire P. Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry. 2012a;69:220–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Fusar-Poli P, McGuire P, Borgwardt S. Mapping prodromal psychosis: a critical review of neuroimaging studies. Eur Psychiatry. 2012b;27:181–91.CrossRefPubMedGoogle Scholar
  57. 57.
    De Herdt A, Wampers M, Vancampfort D, De Hert M, Vanhees L, Demunter H, Van Bouwel L, Brunner E, Probst M. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: a meta-analysis. Schizophr Res. 2013;149:48–55.CrossRefPubMedGoogle Scholar
  58. 58.
    Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkötter J, McGuire P, Yung A. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiat. 2013;70:107–20.CrossRefGoogle Scholar
  59. 59.
    Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Nordentoft M, Raballo A, Meneghelli A, Marshall M, Morrison A, Ruhrmann S, Klosterkötter J. EPA guidance on the early detection of clinical high risk states of psychoses. Eur Psychiatry. 2015;30:405–16.CrossRefPubMedGoogle Scholar
  60. 60.
    Fusar-Poli P, Schultze-Lutter F, Cappucciati M, Rutigliano G, Bonoldi I, Stahl D, Borgwardt S, Riecher-Rössler A, Addington J, Perkins DO, Woods SW, McGlashan T, Lee J, Klosterkötter J, Yung AR, McGuire P. The dark side of the moon: meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42:732–43.CrossRefPubMedGoogle Scholar
  61. 61.
    van der Gaag M, Smit F, Bechdolf A, French P, Linszen DH, Yung AR, McGorry P, Cuijpers P. Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res. 2013;149:56–62.CrossRefPubMedGoogle Scholar
  62. 62.
    Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Meneghelli A, Nordentoft M, Marshall M, Morrison A, Raballo A, Klosterkötter J, Ruhrmann S. EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry. 2015;30:388–404.CrossRefPubMedGoogle Scholar
  63. 63.
    Nielsen RE, Levander S, Kjaersdam Telléus G, Jensen SO, Østergaard Christensen T, Leucht S. Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. Acta Psychiatr Scand. 2015;131:185–96.CrossRefPubMedGoogle Scholar
  64. 64.
    Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951–62.CrossRefPubMedGoogle Scholar
  65. 65.
    Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J. Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review/meta-analysis. Br J Psychiatry. 2014;205:88–94.CrossRefPubMedGoogle Scholar
  66. 66.
    Taylor M, Perera U. Invited commentary on … NICE v. SIGN on psychosis and schizophrenia. Br J Psychiatry. 2016;208:320–1.CrossRefPubMedGoogle Scholar
  67. 67.
    Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, Riedel M, Klingberg S, Köpcke W, Ohmann C, Möller HJ, German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia: maintenance vs. intermittent drug treatment with prodrome-based early intervention. Results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011b;72:205–18.CrossRefPubMedGoogle Scholar
  69. 69.
    Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiat. 2013;70:913–20.CrossRefGoogle Scholar
  70. 70.
    Gaebel W, Wunderink L, Riesbeck M. Early medication discontinuation in first episode schizophrenia—beneficial or risky? Die Psychiatrie. 2016;13:136–44.CrossRefGoogle Scholar
  71. 71.
    Bellack AS. Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications. Schizophr Bull. 2006;32:432–42.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Kane JM, Schooler NR, Marcy P, Correll CU, Brunette MF, Mueser KT, Rosenheck RA, Addington J, Estroff SE, Robinson J, Penn DL, Robinson DG. The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry. 2015;76:240–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Mueser KT, Penn DL, Addington J, Brunette MF, Gingerich S, Glynn SM, Lynde DW, Gottlieb JD, Meyer-Kalos P, McGurk SR, Cather C, Saade S, Robinson DG, Schooler NR, Rosenheck RA, Kane JM. The NAVIGATE Program for first-episode psychosis: rationale, overview, and description of psychosocial components. Psychiatr Serv. 2015;66:680–90.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Kane JM, Robinson DG, Schooler NR, Mueser KT, Penn DL, Rosenheck RA, Addington J, Brunette MF, Correll CU, Estroff SE, Marcy P, Robinson J, Meyer-Kalos PS, Gottlieb JD, Glynn SM, Lynde DW, Pipes R, Kurian BT, Miller AL, Azrin ST, Goldstein AB, Severe JB, Lin H, Sint KJ, John M, Heinssen RK. Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE Early Treatment Program. Am J Psychiatry. 2016;173:362–72.CrossRefPubMedGoogle Scholar
  75. 75.
    Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P. Treatments of negative symptoms in schizophrenia: meta-analysis of 168 randomized placebo-controlled trials. Schizophr Bull. 2015;41:892–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Keshavan MS, Lawler AN, Nasrallah HA, Tandon R. New drug developments in psychosis: challenges, opportunities and strategies. Prog Neurobiol. 2017;152:3–20. Scholar
  77. 77.
    Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M. Celecoxib adjunctive treatment to antipsychotics in schizophrenia: a review of randomized clinical add-on trials. Mediat Inflamm. 2016;2016:3476240. Scholar
  78. 78.
    Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27:879–911.CrossRefPubMedGoogle Scholar
  79. 79.
    Scarff JR. Brexpiprazole: a new treatment option for schizophrenia. Innov Clin Neurosci. 2016;13:26–9.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Moghaddam B. A mechanistic approach to preventing schizophrenia in at-risk individuals. Neuron. 2013;78:1–3.CrossRefPubMedGoogle Scholar
  81. 81.
    Marín O. Developmental timing and critical windows for the treatment of psychiatric disorders. Nat Med. 2016;22(11):1229–38.CrossRefPubMedGoogle Scholar
  82. 82.
    Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. BMC Med. 2013;11:126. Scholar
  83. 83.
    Kozak MJ, Cuthbert BN. The NIMH research domain criteria initiative: background, issues, and pragmatics. Psychophysiology. 2016;53(3):286–97.CrossRefPubMedGoogle Scholar
  84. 84.
    Leboyer M, Berk M, Yolken RH, Tamouza R, Kupfer D, Groc L. Immuno-psychiatry: an agenda for clinical practice and innovative research. BMC Med. 2016;14(1):173.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Carpenter W, Regier D. Diagnostic categories: provisional, not otherwise classified, or place-holder? Schizophr Bull. 2016;42:1305–6.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Wolfgang Gaebel
    • 1
    • 2
    • 3
    Email author
  • Mathias Riesbeck
    • 1
  • Veronica W. Larach
    • 4
  • Peter Falkai
    • 5
  • Jürgen Zielasek
    • 2
    • 3
  1. 1.Department of Psychiatry and Psychotherapy, Medical FacultyHeinrich Heine University DüsseldorfDüsseldorfGermany
  2. 2.WHO Collaborating Center for Quality Assurance and Empowerment in Mental HealthDüsseldorfGermany
  3. 3.LVR Institute for Healthcare ResearchDüsseldorfGermany
  4. 4.Unidad de Psiquiatría, Facultad de MedicinaUniversidad Andrés BelloSantiagoChile
  5. 5.Department of Psychiatry and PsychotherapyLudwig Maximilian University of MunichMunichGermany

Personalised recommendations